Assessing Commercial Tissue-Based Assays for Autoimmune Neurologic Disorders (II)

BACKGROUND AND OBJECTIVES: Detecting neural surface antibodies (NSAbs) is essential for diagnosing autoimmune encephalitis. The recommended diagnostic strategy involves initial screening with tissue-based assays (TBAs), followed by confirmation with cell-based assays (CBAs). While specialized centers use in-house TBAs, many clinical laboratories depend on commercial TBAs, whose accuracy is yet to be fully assessed. METHODS: We selected 92 CSF and 99 serum samples from patients with autoimmune encephalitis and NSAbs confirmed by in-house TBAs and CBAs (20 samples each for AMPAR, GABAAR, GABABR, IgLON5, LGI1, NMDAR, and CASPR2; 19 for mGluR5; 17 for DPPX; and 15 for mGluR1 antibodies), along with 50 CSF and 50 serum samples from negative controls. We assessed the performance of a commercial indirect immunofluorescence (IIF)-TBA (EUROIMMUN). Slides were evaluated as "positive" or "negative" by 2 experienced investigators and 2 less experienced raters. Discordant results were re-evaluated through interrater discussion and assessed using Cohen's kappa. RESULTS: The experienced raters agreed on 94% (133/142) of CSF and 88% (131/149) of serum classifications (Cohen's kappa = 0.87 and 0.75, respectively, p < 0.001). Among CSF samples, 75% (106/142) were correctly identified while 19% (27/142) were misclassified (13 false positives, 14 false negatives). Among serum samples, 66% (98/149) were correctly identified while 22% (33/149) were misclassified (11 false positives, 22 false negatives). The poorest performance was seen in detecting NMDAR, GABAAR, and mGluR5 Abs, which were not identified in 5 of 10, 6 of 10, and 5 of 9 serum samples and in 4 of 10, 5 of 10, and 5 of 10 CSF samples, respectively. The overall sensitivity of the commercial IIF-TBA was 84% for CSF and 76% for serum while the specificity was 72% for CSF and 73% for serum. Less experienced raters correctly identified 69% (98/142) of CSF samples and 73% (109/149) of serum samples and misclassified 13% (18/142) of CSF samples and 11% (16/149) of serum samples, and 18% (26/142) of CSF samples and 16% (24/149) of serum samples remained discordant. DISCUSSION: The diagnostic performance of EUROIMMUN IIF-TBA in detecting NSAbs in autoimmune encephalitis is suboptimal. NMDAR antibodies, among the most common NSAbs, can be missed in 50% of cases. This commercial TBA should not be used alone as a screening method nor as a confirmatory technique for NSAbs.